Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets

Jayasooriya, Anura P.; Sakono, Masafumi; Yukizaki, Chizuko; Kawano, Mikio; Yamamoto, Kyosuke; Fukuda, Nobuhiro

doi:10.1016/s0378-8741(00)00259-2

Cited by 197 publications

(142 citation statements)

References 14 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Indeed, the juice or whole powder of bitter gourd fruit has been reported to have various medicinal properties, including anticarcinogenic [20], hypoglycemic [13,16,24,36], and hypotriglyceridemic [15] effects. These effects are closely related to the role of PPAR in regulating lipid and glucose homeostasis, cellular differentiation and apoptosis, and cancer development as well as in controlling the inflammatory response [17].…”

Section: Discussionmentioning

confidence: 99%

“…These observations implied that bitter gourd, with the characteristic of PPAR a/c dual agonist, may have potential health benefit for ameliorating hyperglycemic and hyperlipidemic conditions [13,15,16,24]. In this study, we fractionated and identified the active compound that can activate PPARa in wild bitter gourd and estimated the content and distribution of the active compound in wild bitter gourd.…”

Section: Introductionmentioning

confidence: 96%

“…The most noteworthy health benefit of bitter gourd are the hypoglycemic potential demonstrated in normal [36] and diabetic [2,7,27,31] rats as well as in human subjects with type II diabetes mellitus [21] and its hypolipidemic effect [3,15,26,29]. The mechanism for the hypoglycemic effect of bitter gourd is still unclear, although it has been shown to inhibit glucose absorption [23], promote hepatic glucose utilization [31], possess an insulin-like polypeptide [18], and even to increase the insulin-positive cell number in the pancreas [1].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARα in bitter gourd (Momordica charantia L.)

et al. 2006

View full text Add to dashboard Cite

SummaryBitter gourd (Momordica charantia L.) is a common vegetable in Asia that has been used in traditional medicine for the treatment of Diabetes. PPARs are ligand-dependent transcription factors that belong to the steroid hormone nuclear receptor family and control lipid and glucose homeostasis in the body. We previously reported that the ethyl acetate (EA) extract of bitter gourd activated peroxisome proliferator receptors (PPARs) a and c. To identify the active compound that activated PPARa, wild bitter gourd EA extract was partitioned between n-hexane and 90% methanol/10% H 2 O, and the n-hexane soluble fraction was further separated by silica gel column chromatography and finally by preparative HPLC. A transactivation assay employing a clone of CHOK1 cells stably transfected with a (UAS) 4 -tk-alkaline phosphatase reporter and a chimeric receptor of GAL4-rPPARa LBD was used to track the active component. Based on Mass, NMR, and IR spectroscopy, 9cis, 11trans, 13trans-conjugated linolenic acid (9c, 11t, 13t-CLN) was identified as a PPARa activator in wild bitter gourd. The isolated 9c, 11t, 13t-CLN rich fraction also significantly induced acyl CoA oxidase (ACO) activity in a peroxisome proliferator-responsive murine hepatoma cell line, H4IIEC3, implying that 9c, 11t, 13t-CLN was able to act on a natural PPARa signaling pathway as well. The content of 9c, 11t, 13t-CLN was estimated to be about 7.1 g/kg of our dried wild bitter gourd sample. The concentration of 9c, 11t, 13t-CLN and activation activity in the hydrolyzed EA extract of the seeds was higher than that of the flesh. The potential health benefits of 9c, 11t, 13t-CLN through the PPARa regulated mechanism are worthy to be further characterized in in vivo studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARα in bitter gourd (Momordica charantia L.)

et al. 2006

View full text Add to dashboard Cite

show abstract

“…In particular, M. charantia improves glucose tolerance and suppresses postprandial hyperglycaemia in rats [71,75,73] , and M. charantia extract can enhance insulin sensitivity and lipolysis [89,90] . Some studies also claimed that the hypoglycaemic effect of M. charantia was comparable with oral medications such as tolbutamide [70,91] , chlorpropamide and glibenclamide [92,93] . Abundant biochemical data have shed light upon possible mechanisms of the anti-diabetic actions of M. charantia with the recurring theme being activation of the AMP-activated protein kinase system [94][95][96][97] .…”

Section: Animal Studies Of M Charantiamentioning

confidence: 99%

Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency

Joseph¹,

Jini²

2013

Asian Pacific Journal of Tropical Disease

387

252

View full text Add to dashboard Cite

“…In addition to blood glucose regulation, data from multiple animal models have demonstrated the positive effects of bitter melon in the treatment of various diabetes complications, including nephropathy [30], neuropathy and enteropathy [31], insulin resistance and cataract development [32], while positive effects on other markers of metabolic syndrome, including reduced LDL-cholesterol and triglyceride levels, have also been demonstrated in rat models [33][34][35][36][37].…”

Section: Bitter Melon: Momordica Charantia L (Cucurbitaceae)mentioning

confidence: 99%

Plant derived therapeutics for the treatment of Metabolic Syndrome

Cefalu¹

2011

Planta Med

View full text Add to dashboard Cite

Metabolic syndrome is defined as a set of coexisting metabolic disorders that increase an individual's likelihood of developing type 2 diabetes, cardiovascular disease and stroke. Medicinal plants, some of which have been used for thousands of years, serve as an excellent source of bioactive compounds for the treatment of metabolic syndrome because they contain a wide range of phytochemicals with diverse metabolic effects. In order for botanicals to be effectively used against metabolic syndrome, however, botanical preparations must be characterized and standardized through the identification of their active compounds and respective modes of action, followed by validation in controlled clinical trials with clearly defined endpoints. This review assesses examples of commonly known and partially characterized botanicals to describe specific considerations for the phytochemical, preclinical and clinical characterization of botanicals associated with metabolic syndrome.

show abstract

Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets

Cited by 197 publications

References 14 publications

Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARα in bitter gourd (Momordica charantia L.)

Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARα in bitter gourd (Momordica charantia L.)

Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency

Plant derived therapeutics for the treatment of Metabolic Syndrome

Contact Info

Product

Resources

About